MX2019005627A - Terapias combinadas para la ateroesclerosis, incluyendo la enfermedad cardiovascular ateroesclerotica. - Google Patents

Terapias combinadas para la ateroesclerosis, incluyendo la enfermedad cardiovascular ateroesclerotica.

Info

Publication number
MX2019005627A
MX2019005627A MX2019005627A MX2019005627A MX2019005627A MX 2019005627 A MX2019005627 A MX 2019005627A MX 2019005627 A MX2019005627 A MX 2019005627A MX 2019005627 A MX2019005627 A MX 2019005627A MX 2019005627 A MX2019005627 A MX 2019005627A
Authority
MX
Mexico
Prior art keywords
atherosclerosis
pcsk9
ldl
therapies
cardiovascular disease
Prior art date
Application number
MX2019005627A
Other languages
English (en)
Inventor
Wasserman Scott
Andrew Donald Scott Robert
Mudalinayake Somaratne Ransi
Honarpour Narimon
Nicholls Stephen
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=60484496&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2019005627(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of MX2019005627A publication Critical patent/MX2019005627A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Microbiology (AREA)
  • Cardiology (AREA)
  • Mycology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

En el presente documento se proporcionan combinaciones de terapias que posibilitan el tratamiento, incluyendo la regresion, de la ateroesclerosis y/o la mejora de los resultados cardiovasculares. Descrito de modo general, esto incluye un primer agente reductor del LDL-C distinto de PCSK9 (tal como una estatina u otra terapia reductora de LDL-C distinta de PCSK9), combinado con una segunda terapia con inhibidor de PCSK9 (tal como un anticuerpo contra PCSK9 o anti-ARN). Se ha determinado que la aplicacion de ambas terapias, a niveles adecuadamente elevadas a fin de reducir el nivel de LDL-C del sujeto hasta niveles muy bajos, durante un periodo de tiempo adecuado, proporciona un beneficio anadido de proteccion adicional frente a la ateroesclerosis y mejora los resultados cardiovasculares de un sujeto.
MX2019005627A 2016-11-14 2017-11-13 Terapias combinadas para la ateroesclerosis, incluyendo la enfermedad cardiovascular ateroesclerotica. MX2019005627A (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201662421685P 2016-11-14 2016-11-14
US201762471874P 2017-03-15 2017-03-15
US201762515117P 2017-06-05 2017-06-05
US201762581244P 2017-11-03 2017-11-03
US201762584600P 2017-11-10 2017-11-10
PCT/US2017/061346 WO2018089912A2 (en) 2016-11-14 2017-11-13 Combined therapies for atherosclerosis, including atherosclerotic cardiovascular disease

Publications (1)

Publication Number Publication Date
MX2019005627A true MX2019005627A (es) 2019-10-14

Family

ID=60484496

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019005627A MX2019005627A (es) 2016-11-14 2017-11-13 Terapias combinadas para la ateroesclerosis, incluyendo la enfermedad cardiovascular ateroesclerotica.

Country Status (17)

Country Link
US (1) US20200368350A1 (es)
EP (1) EP3538149A2 (es)
JP (2) JP2019533715A (es)
KR (1) KR20190085963A (es)
CN (1) CN110234350A (es)
AU (1) AU2017356219A1 (es)
BR (1) BR112019009726A2 (es)
CA (1) CA3043700A1 (es)
CL (2) CL2019001304A1 (es)
CO (1) CO2019004814A2 (es)
IL (1) IL266579A (es)
JO (1) JOP20190112A1 (es)
MA (1) MA46758A (es)
MX (1) MX2019005627A (es)
TN (1) TN2019000156A1 (es)
WO (1) WO2018089912A2 (es)
ZA (1) ZA201902975B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2954767A1 (en) * 2014-07-14 2016-01-21 Amgen Inc. Crystalline antibody formulations
JOP20190215A1 (ar) 2017-03-24 2019-09-19 Ionis Pharmaceuticals Inc مُعدّلات التعبير الوراثي عن pcsk9
CN113271931A (zh) * 2018-07-31 2021-08-17 谭文 氨基甲酸酯β苯乙醇胺类似物增强胞内LDL胆固醇的清除及与他汀类药物联用的新用途
WO2021012074A1 (en) * 2019-07-19 2021-01-28 Ebay Inc. Sample delta monitoring
CN112656792B (zh) * 2021-01-26 2022-07-05 首都医科大学宣武医院 洛美他派在制备用于治疗脑卒中引起的神经损伤药物中的用途

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101484588B (zh) 2006-05-11 2013-11-06 阿尔尼拉姆医药品有限公司 抑制pcsk9基因表达的组合物和方法
AR070315A1 (es) 2008-02-07 2010-03-31 Merck & Co Inc Anticuerpos 1b20 antagonistas de pcsk9
AR070316A1 (es) 2008-02-07 2010-03-31 Merck & Co Inc Antagonistas de pcsk9 (proproteina subtilisina-kexina tipo 9)
TWI516501B (zh) 2008-09-12 2016-01-11 禮納特神經系統科學公司 Ｐｃｓｋ９拮抗劑類
JO3672B1 (ar) 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
US9493774B2 (en) * 2009-01-05 2016-11-15 Rxi Pharmaceuticals Corporation Inhibition of PCSK9 through RNAi
WO2010148013A2 (en) 2009-06-15 2010-12-23 Alnylam Pharmaceuticals, Inc. Lipid formulated dsrna targeting the pcsk9 gene
AR079336A1 (es) 2009-12-11 2012-01-18 Irm Llc Antagonistas de la pro-proteina convertasa-subtilisina/quexina tipo 9 (pcsk9)
US20120195910A1 (en) 2010-12-22 2012-08-02 Genentech, Inc. Anti-pcsk9 antibodies and methods of use
EP2673302A1 (en) 2011-02-11 2013-12-18 Irm Llc Pcsk9 antagonists
JOP20200043A1 (ar) * 2011-05-10 2017-06-16 Amgen Inc طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول
AR087715A1 (es) 2011-09-16 2014-04-09 Lilly Co Eli Anticuerpos anti pcsk9 y usos de los mismos
CN107427221B (zh) * 2015-01-09 2021-03-09 全球基因集团有限责任公司 用于诊断冠状动脉粥样硬化性疾病的基于血液的生物标志物
EA039310B1 (ru) * 2015-02-26 2022-01-12 Санофи Байотекнолоджи Способы снижения сердечно-сосудистого риска

Also Published As

Publication number Publication date
BR112019009726A2 (pt) 2019-08-13
JP2019533715A (ja) 2019-11-21
MA46758A (fr) 2019-09-18
CA3043700A1 (en) 2018-05-17
EP3538149A2 (en) 2019-09-18
AU2017356219A1 (en) 2019-05-30
WO2018089912A3 (en) 2018-06-21
JP2023071715A (ja) 2023-05-23
WO2018089912A2 (en) 2018-05-17
KR20190085963A (ko) 2019-07-19
TN2019000156A1 (en) 2020-10-05
CL2019001304A1 (es) 2019-09-23
IL266579A (en) 2019-07-31
CN110234350A (zh) 2019-09-13
CL2020002993A1 (es) 2021-05-14
ZA201902975B (en) 2020-01-29
CO2019004814A2 (es) 2019-07-31
JOP20190112A1 (ar) 2019-05-14
US20200368350A1 (en) 2020-11-26

Similar Documents

Publication Publication Date Title
TN2019000156A1 (en) Combined therapies for atherosclerosis, including atherosclerotic cardiovascular disease
PH12019501575A1 (en) ISOFORM-SPECIFIC, CONTEXT-PERMISSIVE TGFá1 INHIBITORS AND USE THEREOF
WO2017197153A8 (en) Combination therapies of hdac inhibitors and pd-1 inhibitors
MX2021000898A (es) Inhibidores de pcsk9 para usarse en el tratamiento de pacientes con hipercolesterolemia familiar heterocigota (hfhe).
BR112015013123A2 (pt) inibidores de beta-lactamase
WO2015123423A3 (en) Methods for treating patients with hypercholesterolemia that is not adequately controlled by moderate-dose statin therapy
EA201790142A1 (ru) Лечение лейкоза ингибиторами гистондеацетилазы
MX2021010875A (es) Composiciones de éster de ácido cannabinoide y sus usos.
BR112015026021A2 (pt) terapia de combinação compreendendo um inibidor de tor quinase e n-(3-(5-flúor-2-(4-(2-met-oxietoxi)fenilamino)pirimidin-4-ilamino)fenil)acrilamida para o tratamento de câncer
PH12021551282A1 (en) Radioimmunoconjugates and checkpoint inhibitor combination therapy
MA47736B1 (fr) Pyrimidopyrimidinones utiles en tant qu'inhibiteurs de la kinase wee-1
WO2016094834A3 (en) A method for treating a complement mediated disorder caused by an infectious agent in a patient
PH12019502174A1 (en) Modulators of pcsk9 expression
MX2021013354A (es) Metodos para tratar y/o prevenir queratosis actinica.
WO2018052891A3 (en) MODULATION OF PCSK9 AND LDLR BY INHIBITION OF DRP1
MX2017002968A (es) Anticuerpo monoclonal humanizado para inhibir la actividad enzimatica de la lipasa endotelial vascular.
MX2018005352A (es) Metodos y composiciones para el tratamiento de amiloidosis.
MX2021006915A (es) Inhibidores de cxcr7 para el tratamiento de cancer.
AU2018258588A8 (en) Inhibitors of TRIM33 and methods of use
GB2549031A (en) Methods and drug therapies for patency of occluded blood vessels following angioplasty
WO2018049003A8 (en) ANTI-FIBROTIC SIALIDASE INHIBITOR COMPOUNDS AND THEIR METHODS OF USE
MX2020004731A (es) Terapias de combinacion de inhibidor ezh2.
MY166357A (en) Monoclonal antibody, inhibiting the enzymatic activity of vascular endothelial lipase
EA201991160A1 (ru) Средства комбинированной терапии атеросклероза, включая атеросклеротическое сердечно-сосудистое заболевание
AR113874A1 (es) Terapias de combinación de inhibidor ezh2